Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1127030 | 1.00 | CYP2C9 (0.59) | CYP2C9ALDH1A1TSHRMIFMAPT | |
| SCHEMBL23835988 | 1.00 | CYP2C9 (0.59) | CYP2C9ALDH1A1TSHRMIFMAPT | |
| SCHEMBL12674556 | 0.87 | CYP2C9 (0.57) | CYP2C9ALDH1A1TSHRMIFMAPT | |
| SCHEMBL23836013 | 0.86 | CYP2C9 (0.44) | CYP2C9ALDH1A1TSHRMIFMAPT | |
| SCHEMBL27511755 | 0.83 | TP53 (0.44) | CYP2C9ALDH1A1TSHRMIFMAPT | |
| SCHEMBL5554979 | 0.82 | CYP2C9 (0.40) | CYP2C9ALDH1A1TSHRMIFMAPT | |
| SCHEMBL4906704 | 0.82 | CYP2C9 (0.69) | CYP2C9ALDH1A1TSHRMIFMAPT | |
| SCHEMBL4961560 | 0.82 | CYP2C9 (0.69) | CYP2C9ALDH1A1TSHRMIFMAPT | |
| SCHEMBL2755215 | 0.82 | CYP2C9 (0.69) | CYP2C9ALDH1A1TSHRMIFMAPT | |
| SCHEMBL16159975 | 0.81 | KDM4E (0.49) | CYP2C9ALDH1A1TSHRMIFMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
| US-20220402896-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2022-12-22 | — | — | US | disclosed |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20220162194-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11179710-B2 | Direct palladium-catalyzed aromatic fluorination | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210355111-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2021-11-18 | — | — | US | disclosed |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-1192125-B1 | MONO-SUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS | WARNER LAMBERT CO (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20080207755-A1 | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders | PFIZER INC | 2008-08-28 | — | — | US | disclosed |
| US-7381747-B2 | Alpha 2 delta ligands for post-traumatic stress disorder | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1840117-A1 | Mono- and disubstituted 3-propyl gamma-aminobutyric acids | Warner-Lambert Company LLC (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7189747-B2 | Method of treating noninflammatory cartilage damage | WARNER-LAMBERT COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| US-20070027212-A1 | ALPHA 2 DELTA LIGANDS FOR FIBROMYALGIA AND OTHER DISORDERS | PFIZER INC | 2007-02-01 | — | — | US | disclosed |
| US-7164034-B2 | Alpha2delta ligands for fibromyalgia and other disorders | PFIZER INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-7164034-B2 | Alpha2delta ligands for fibromyalgia and other disorders | PFIZER INC. (US) | 2007-01-16 | — | — | US | disclosed |
| WO-2004054566-A1 | PREGABALIN DERIVATIVES FOR THE TREATMENT OF FIBROMYALGIA AND OTHER DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2003063845-A1 | ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTSV, CTRL, CTSL | CYP2C9 377/4885ALDH1A1 1798/4885TSHR 4702/4885 |
| US-20070027212-A1 | ALPHA 2 DELTA LIGANDS FOR FIBROMYALGIA AND OTHER DISORDERS | OPRD1, HCRTR2, OPRL1 | CYP2C9 1641/4885ALDH1A1 1174/4885TSHR 218/4885 |
| US-20220162194-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | CYP2C9 377/4885ALDH1A1 1798/4885TSHR 4702/4885 |
| US-20220402896-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | CYP2C9 377/4885ALDH1A1 1798/4885TSHR 4702/4885 |
| US-20210355111-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | CYP2C9 821/4885ALDH1A1 2252/4885TSHR 4585/4885 |
| US-11179710-B2 | Direct palladium-catalyzed aromatic fluorination | KRAS, NRAS, DDT | CYP2C9 655/4885ALDH1A1 231/4885TSHR 203/4885 |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | CYP2C9 821/4885ALDH1A1 2252/4885TSHR 4585/4885 |
| US-20080207755-A1 | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders | OPRD1, OPRL1, FFAR3 | CYP2C9 1955/4885ALDH1A1 775/4885TSHR 825/4885 |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | CYP2C9 377/4885ALDH1A1 1798/4885TSHR 4702/4885 |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | CYP2C9 821/4885ALDH1A1 2252/4885TSHR 4585/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | CYP2C9 375/4885ALDH1A1 1863/4885TSHR 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.